VERAXA Biotech AG to Merge with Voyager Acquisition Corp.

Xlife Sciences AG announced the merger of VERAXA Biotech AG with Voyager Acquisition Corp., a NASDAQ-listed company. VERAXA Biotech AG is valued at USD 1.64 billion, with expected gross cash proceeds of up to USD 253 million. This strategic merger will list VERAXA as a public company on NASDAQ, under the ticker symbol "VERX".

Based in Switzerland, VERAXA Biotech focuses on cancer therapeutics, pioneering next-generation antibody drug conjugates and T cell engagers. Their new BiTAC platform aims to improve cancer treatment safety. The merger, expected to close in Q4 2025, provides access to funds for advancing therapeutic development.

Oliver R. Baumann, Xlife Sciences' CEO, highlighted the importance of this milestone. VERAXA aims to create first-in-class therapies with enhanced safety and efficacy. This move is anticipated to boost its global market presence and foster new partnerships.